- Home
- BELFB vs AUPH Comparison
BELFB vs AUPH Comparison
Compare BELFB & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- AUPH
- Stock Information
- Founded
- BELFB 1949
- AUPH 1993
- Country
- BELFB United States
- AUPH Canada
- Employees
- BELFB N/A
- AUPH N/A
- Industry
- BELFB
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- BELFB
- AUPH Health Care
- Exchange
- BELFB Nasdaq
- AUPH Nasdaq
- Market Cap
- BELFB 1.8B
- AUPH 1.6B
- IPO Year
- BELFB N/A
- AUPH 1999
- Fundamental
- Price
- BELFB $160.41
- AUPH $14.57
- Analyst Decision
- BELFB Strong Buy
- AUPH Strong Buy
- Analyst Count
- BELFB 4
- AUPH 3
- Target Price
- BELFB $153.75
- AUPH $17.67
- AVG Volume (30 Days)
- BELFB 173.9K
- AUPH 1.7M
- Earning Date
- BELFB 10-29-2025
- AUPH 11-04-2025
- Dividend Yield
- BELFB 0.17%
- AUPH N/A
- EPS Growth
- BELFB 19.52
- AUPH N/A
- EPS
- BELFB 5.17
- AUPH 0.55
- Revenue
- BELFB $649,376,000.00
- AUPH $265,808,000.00
- Revenue This Year
- BELFB $26.78
- AUPH $17.33
- Revenue Next Year
- BELFB $6.19
- AUPH $14.31
- P/E Ratio
- BELFB $30.57
- AUPH $26.56
- Revenue Growth
- BELFB 23.70
- AUPH 20.62
- 52 Week Low
- BELFB $58.00
- AUPH $6.55
- 52 Week High
- BELFB $161.66
- AUPH $16.20
- Technical
- Relative Strength Index (RSI)
- BELFB 61.76
- AUPH 72.40
- Support Level
- BELFB $143.13
- AUPH $13.34
- Resistance Level
- BELFB $160.70
- AUPH $16.20
- Average True Range (ATR)
- BELFB 8.16
- AUPH 0.72
- MACD
- BELFB 0.40
- AUPH 0.29
- Stochastic Oscillator
- BELFB 96.16
- AUPH 65.68
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.